Program
QL2107
Also written as “QLS5132; QL1706; QL2107”, “QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin” and “QLC1101+QL2107”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 55 open or running | phase 3since Dec 23, 2024 | Nov 29, 2023 | Dec 2026phase 3 · NCT06754644 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06173011 · 168 planned · China
- Dec 23, 2024Phase 3 study in NSCLCNCT06754644 · 808 planned · China
- Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
- Aug 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07162883 · 146 enrolled · Bosnia and Herzegovina, China, Georgia and more
- Mar 1, 2026Phase 2 study in Stomach NeoplasmsNCT07453394 · 626 planned
Ahead
- Dec 2026Primary completion: phase 3 study in NSCLCNCT06754644
- Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07162883
- Apr 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07453394
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07453394Stomach Neoplasms | 2 | Not yet recruiting | Apr 2027 | 626 |
| NCT07162883Carcinoma, Non-Small-Cell Lung · Bosnia and Herzegovina, China, Georgia and more | 3 | Active, not recruiting | Dec 31, 2026 | 146 |
| NCT06949761Solid Tumor | 2 | Not yet recruiting | Sep 2026 | 240 |
| NCT06754644NSCLC · China | 3 | Recruiting | Dec 2026 | 808 |
| NCT06173011Neoplasms · China | 1 | Recruiting | Jul 2024 | 168 |
How it is read
Names in the registry
- “QL2107”, 3 entries
- “QLS5132; QL1706; QL2107”, 1 entry
- “QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin”, 1 entry
- “QLC1101+QL2107”, 1 entry
Codes read as this program: QL2107.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Stomach Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.